SEPT6-ABL2 fusion for use in the diagnosis and/or treatment of cancer

Patent number:

PCT/EP2022/065750; EP21382663

No items found.

The present invention refers to a cell line characterized by comprising the fusion gene [SEPT6-ABL2] within its genetic material, or the fusion transcript [SEPT6-ABL2], and also to the use of [SEPT6-ABL2] fusion in a method for the diagnosis and/or treatment of cancer.

Countries:

Spain

Regions:

Community of Madrid

Centers:

UNIVERSIDAD AUTONOMA DE MADRID, FUNDACION INSTITUTO DE INVESTI GACION SANITARIA FUNDACION JIMENEZ DIAZ

Other entities:

Sectors:

Health

Subsectors:

TRL Level:

TRL 5 – technology validated in relevant environment (industrially relevant environment in the case of key enabling technologies)

BRL Level:

PDF Link:

Download here

Video Link:

Watch it here

Sustainable Development Goal:

SDG03: Good health and well-being

Applications

The present invention refers to the medical field. Particularly, the present invention refers to a cell line characterized by comprising the fusion gene [SEPT6-ABL2] within its genetic material, or the fusion transcript [SEPT6-ABL2]. The present invention is also focused on the use of SEPT6-ABL2 fusion in a method for the diagnosis and/or treatment of cancer.

Comments

Other related patents

Health

Miniaturised diffractive analysis device without the need for marking

Countries

Spain

Health

Method and system for monitoring exercises with elastic elements

Countries

Spain

Health

USE OF PHARMACOLOGICAL CHAPERONES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES

Countries

Spain

Get back to patents directory